Graphite Bio Stock Fundamentals
| GRPHDelisted Stock | USD 2.67 0.05 1.84% |
Graphite Bio fundamentals help investors to digest information that contributes to Graphite Bio's financial success or failures. It also enables traders to predict the movement of Graphite Stock. The fundamental analysis module provides a way to measure Graphite Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Graphite Bio stock.
Graphite |
Graphite Bio Company Current Valuation Analysis
Graphite Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Graphite Bio Current Valuation | 1.88 M |
Most of Graphite Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Graphite Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Graphite Bio has a Current Valuation of 1.88 M. This is 99.99% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Graphite Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Graphite Bio's current stock value. Our valuation model uses many indicators to compare Graphite Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Graphite Bio competition to find correlations between indicators driving Graphite Bio's intrinsic value. More Info.Graphite Bio is rated below average in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Graphite Bio's earnings, one of the primary drivers of an investment's value.Graphite Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Graphite Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Graphite Bio could also be used in its relative valuation, which is a method of valuing Graphite Bio by comparing valuation metrics of similar companies.Graphite Bio is currently under evaluation in current valuation category among its peers.
Graphite Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | 1.88 M | |||
| Shares Outstanding | 58.24 M | |||
| Shares Owned By Insiders | 9.17 % | |||
| Shares Owned By Institutions | 84.40 % | |||
| Number Of Shares Shorted | 704.04 K | |||
| Price To Earning | 0.70 X | |||
| Price To Book | 1.01 X | |||
| EBITDA | (70.7 M) | |||
| Net Income | (124.65 M) | |||
| Cash And Equivalents | 322.29 M | |||
| Cash Per Share | 5.54 X | |||
| Total Debt | 362 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 27.07 X | |||
| Book Value Per Share | 3.17 X | |||
| Cash Flow From Operations | (90.01 M) | |||
| Short Ratio | 7.93 X | |||
| Earnings Per Share | (2.19) X | |||
| Price To Earnings To Growth | (0.08) X | |||
| Target Price | 7.0 | |||
| Beta | 0.2 | |||
| Market Capitalization | 189.84 M | |||
| Total Asset | 188.46 M | |||
| Retained Earnings | (367.05 M) | |||
| Working Capital | 183.22 M | |||
| Current Asset | 8 K | |||
| Current Liabilities | 451 K | |||
| Annual Yield | 0.30 % | |||
| Net Asset | 188.46 M |
About Graphite Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Graphite Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Graphite Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Graphite Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Graphite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Graphite Stock
If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |